Speaker(s): 

Miranda Woosman PharmD, PGY1 resident, Geisinger - has nothing to disclose.

Moderator(s): 

Christopher J DeFrancesco PharmD, Geisinger - has nothing to disclose.

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1. Recognize common immune checkpoint inhibitor toxicities and their clinical presentations. 

2. Apply appropriate treatment strategies based on the severity and type of immune checkpoint inhibitor-related toxicity. 

3. Describe general principles guiding continuation, holding, or discontinuation of immune checkpoint inhibitors in the setting of toxicity. 

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Christopher DeFrancesco PharmD, RPH, Anil Singh MD, Roop Parlapalli, MD, FHM, FACP, Mary Ellen Berry PA-C, and Carlena Miller CRNP have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None